Trials / Unknown
UnknownNCT05335538
TruGraf and TRAC In Pediatrics Study
The Role of TruGraf® to Optimize Outcomes in Pediatric Renal Transplantation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (estimated)
- Sponsor
- Transplant Genomics, Inc. · Industry
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot 3 center prospective study of pediatric renal kidney recipients undergoing protocol biopsies examining the performance of the TruGraf gene expression test in children and adolescents.
Detailed description
In pediatric renal transplant recipients, subclinical rejection in protocol biopsies is associated with a significantly increased incidence of acute rejection and/or allograft loss at 5 years post-transplant. Currently, TruGraf is the only noninvasive test designed and validated in adult kidney transplant recipients for use in ruling out silent subacute rejection in that has been approved by Medicare as an alternative to surveillance biopsies. The first step to the use of TruGraf in pediatrics is to perform a validation study in children and adolescents. Specifically, if validated in children and adolescents, a TruGraf result would enable a pediatric transplant physician to identify patients in whom no intervention is necessary without the need of a protocol biopsy. Therefore the aim of this study is to examine the concordance between the results of the TruGraf tests and protocol biopsies taken from stable pediatric renal transplant patients concurrently.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Patients monitored with TruGraf and TRAC testing | This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management. |
Timeline
- Start date
- 2021-11-30
- Primary completion
- 2022-12-30
- Completion
- 2023-03-01
- First posted
- 2022-04-19
- Last updated
- 2022-04-19
Locations
3 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT05335538. Inclusion in this directory is not an endorsement.